Zhifei Biological's controlling subsidiary, Chengan Bio, has secured marketing approval for its Degludec Aspart Insulin Injection. This combination insulin product offers a new therapeutic option for managing diabetes. The approval underscores Chengan Bio's ongoing efforts to diversify its insulin product line and meet patient needs.
The approval of Degludec Aspart Insulin Injection by Chengan Bio expands Zhifei Biological's offerings in the diabetes care market. Combination insulin products can improve patient adherence and glycemic control. This strategic move strengthens Zhifei's competitive position against other insulin manufacturers and contributes to its revenue diversification.
Chengan Bio's Degludec Aspart Insulin Injection receives marketing approval.
Expands Zhifei's portfolio of diabetes treatment options.
Offers a combination insulin for improved patient management.
This product launch is relevant to the East Asian market, particularly China, where the prevalence of diabetes necessitates a range of effective and convenient treatment options. The combination insulin addresses a key need for improved patient management.
Offers a combination insulin for improved patient management.
Strengthens competitive standing in the diabetes care market.
Sign in to save notes on signals.
Sign In